CHC – The Cancer & Hematology Centers

D361BC00001 (CAPITELLO-281)

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency

CC-94676-  (Celgene)

CC-94676-  (Celgene) Description:  A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CC-94676 In Subjects With Metastatic Castration-Resistant Prostate Cancer Target Patient Population:  Prostate Cancer Study Design:  Drug is given orally daily.